Attenuated fibrosis in specific pathogen-free microbiota in experimental cholestasis- and toxin-induced liver injury.
altered Schaedler flora
bile duct ligation
carbon tetrachloride
portal hypertension
α-SMA
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
pubmed:
23
8
2019
medline:
27
5
2020
entrez:
22
8
2019
Statut:
ppublish
Résumé
In advanced chronic liver disease (CLD), the translocation of intestinal bacteria and the resultant increase of proinflammatory cytokines in the splanchnic and systemic circulation may contribute to the progression of fibrosis. We therefore speculated that fibrosis and portal hypertension (PHT) would be attenuated in a mouse model of limited intestinal colonization with altered Schaedler flora (ASF) compared to a more complex colonization with specific pathogen-free (SPF) flora. We induced liver fibrosis in ASF and SPF mice by common bile duct ligation (BDL) or by carbon tetrachloride (CCl
Identifiants
pubmed: 31431085
doi: 10.1096/fj.201901113R
pmc: PMC6902738
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12464-12476Références
Gastroenterology. 2012 Apr;142(4):865-874.e2
pubmed: 22202458
J Hepatol. 2012 Jun;56(6):1283-92
pubmed: 22326468
Nature. 2014 Sep 4;513(7516):59-64
pubmed: 25079328
Gastroenterology. 2014 May;146(6):1513-24
pubmed: 24440671
Hepatology. 2008 Jul;48(1):322-35
pubmed: 18506843
Br J Surg. 2008 May;95(5):646-56
pubmed: 18196571
Nat Commun. 2015 Sep 22;6:8292
pubmed: 26392213
Toxicol Lett. 2014 Jan 13;224(2):186-95
pubmed: 24188933
J Hepatol. 2015 Apr;62(1 Suppl):S121-30
pubmed: 25920081
Cell Mol Immunol. 2014 May;11(3):224-31
pubmed: 24633014
J Hepatol. 2006 Feb;44(2):383-90
pubmed: 16221502
Hepatobiliary Surg Nutr. 2014 Dec;3(6):386-406
pubmed: 25568862
Gut. 2019 Mar;68(3):578-580
pubmed: 29581241
FASEB J. 2015 Mar;29(3):1043-55
pubmed: 25466902
Gastroenterology. 2008 May;134(6):1655-69
pubmed: 18471545
PLoS One. 2014 Mar 25;9(3):e92515
pubmed: 24667392
J Hepatol. 2014 May;60(5):1090-6
pubmed: 24412603
Nat Rev Immunol. 2008 Jun;8(6):411-20
pubmed: 18469830
J Hepatol. 2009 Dec;51(6):1037-45
pubmed: 19716616
Biochem Biophys Res Commun. 1999 Mar 24;256(3):527-31
pubmed: 10080931
Cell Host Microbe. 2016 Nov 9;20(5):561-571
pubmed: 27832587
Semin Immunol. 2007 Apr;19(2):59-69
pubmed: 17118672
J Clin Invest. 2007 Aug;117(8):2313-24
pubmed: 17641781
Gastroenterology. 2007 Oct;133(4):1210-8
pubmed: 17919495
J Hepatol. 2014 Jan;60(1):197-209
pubmed: 23993913
J Hepatol. 1995 Feb;22(2):165-72
pubmed: 7790704
Cell. 2017 Nov 16;171(5):1015-1028.e13
pubmed: 29056339
J Hepatol. 2014 Dec;61(6):1385-96
pubmed: 25135860
Hepatology. 2003 Aug;38(2):355-63
pubmed: 12883479
J Exp Med. 1965 Jul 1;122:59-66
pubmed: 14325473
Nat Med. 2007 Nov;13(11):1324-32
pubmed: 17952090
Hepatology. 2016 Jan;63(1):185-96
pubmed: 26044703
Int J Microbiol. 2012;2012:694629
pubmed: 22848224
World J Gastroenterol. 2007 Dec 28;13(48):6458-64
pubmed: 18161914
Front Immunol. 2019 Feb 05;10:167
pubmed: 30804947
Am J Physiol. 1982 Feb;242(2):G156-60
pubmed: 7065143
J Hepatol. 2017 Nov;67(5):1084-1103
pubmed: 28526488
Gut. 2016 Dec;65(12):2035-2044
pubmed: 27802157
Lab Invest. 2010 Jun;90(6):844-52
pubmed: 20368698